Other
Current maturities of long-term debt
This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ4 2020
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase signals higher immediate debt service requirements, which may necessitate refinancing or use of cash reserves.
Detailed definition
This reflects the portion of long-term debt and finance lease obligations that must be repaid within the next fiscal yea...
Peer comparison
Commonly tracked across all capital-intensive industries to evaluate short-term solvency.
Metric ID:
other_finance_lease_liability_currentHistorical Data
9 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $718.40M | $719.00M | $719.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $720.00M |
| QoQ Change | — | +0.1% | +0.1% | -100.0% | — | — | — | — | — |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | — | — |
Range$0.00 – $720.00M
CAGR+0.1%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Current maturities of long-term debt at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's current maturities of long-term debt?
- Regeneron Pharmaceuticals (REGN) reported current maturities of long-term debt of $720.00M in Q1 2026.
- What does current maturities of long-term debt mean?
- The portion of long-term debt and finance lease obligations maturing within the next twelve months.